Core Insights - Positron Corporation has announced a partnership with MedAxiom to enhance the adoption of PET imaging technology in cardiovascular care [1][3][4] Company Overview - Positron Corporation specializes in the development, manufacturing, and sale of advanced PET and PET-CT imaging systems and clinical services for nuclear medicine healthcare providers in North America [5][6] - The company focuses on cardiac Positron Emission Tomography (PET) imaging, which is considered the gold standard in cardiac diagnostics [6][7] Partnership Details - The collaboration with MedAxiom connects Positron to leading cardiovascular organizations, providing access to valuable insights and exposure that can advance the adoption of PET technology [3][4] - MedAxiom is recognized for its extensive network and for driving innovation in cardiovascular medicine, which will benefit Positron in terms of market intelligence and clinical insights [2][3] Market Position and Technology - Positron's unique market position and innovative PET/PET-CT technologies are expected to facilitate the growth of the nuclear imaging market [7] - The company plans to introduce a state-of-the-art PET-CT 4D molecular imaging device, the Affinity PET-CT 4D 64-Slice, which will enhance the capabilities of nuclear cardiologists [7][8] Commitment to Advancement - Positron is dedicated to expanding the cardiac and oncology PET modalities by delivering high-quality technology and value to imaging specialists [8]

Core Viewpoint - Positron Corporation has successfully sold its NeuSight PET-CT 64-slice scanner to a leading nuclear cardiologist, indicating a growing demand for its advanced imaging solutions in the healthcare sector [1][2]. Group 1: Product and Technology - The NeuSight PET-CT scanner is designed to enhance cardiac PET imaging with advanced technology, high sensitivity, and a spacious 72 cm gantry, which reduces radiation exposure for patients and staff [3]. - This imaging system is versatile, providing high-performance imaging for both cardiology and oncology applications, and supports a wide range of studies including cardiac, tumor, and neurological imaging [4]. - Positron's upcoming Affinity PET-CT 4D 64-Slice device will further enhance its offerings in the nuclear imaging market, enabling comprehensive capabilities for nuclear cardiologists [8]. Group 2: Market Position and Strategy - The sale to a respected physician reflects the increasing recognition of Positron's advanced PET imaging systems and full-service support, positioning the company to expand its market presence, particularly in the western U.S. [5]. - Positron specializes in cardiac PET imaging, which is considered the gold standard in cardiac diagnostics, allowing healthcare providers to accurately diagnose coronary artery disease while maintaining cost-effective practices [7]. - The company's unique market position and innovative technologies are expected to facilitate the adoption of cardiac PET and drive growth in the nuclear imaging market [8]. Group 3: Commitment to Innovation - Positron is dedicated to advancing cardiac and oncology PET modalities by delivering superior technology and value to imaging specialists, supported by its collaboration with Shenyang Intelligent Neuclear Technology Co. [9].